Contributions
Abstract: EP1368
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - MS and gender
Introduction: It is known that exacerbations in the first year after childbirth are associated with the progression of the disease. However, data on the evaluation of various factors on the postpartum relapse's risk is not enough.
Objective: to evaluate MRI data before and after pregnancy.
Methods: A retrospective analysis from 2011 to 2017 of SPbMS Center registry was performed. For the analysis, the data were selected during observation for 1 year after delivery and without the use of 2-line drugs during pregnancy and the first months after childbirth. MRI data before pregnancy (n=92) and 1-3 mo after delivery (n=94) were assessed. Statistical analysis was performed with the program GraphPad Prism v7.0
Results: 127 women (133 births) were enrolled in the study. In the patient milestones there was a relapsing-remitting MS. AAR during pregnancy significantly decreased to 0.08 (p < 0.0001) and returned to the previous level 0.5 after delivery (p < 0.0001). When registering contrast lesions (Gd +) before pregnancy, the probability of exacerbations after childbirth is increased by 2.2 times (95% CI 1.08-4.9, p = 0.048). The existence of Gd+ immediately after delivery increased the probability of exacerbation by 5.8 times (95% CI: 2.83, 9.93, p < 0.0001). AUC was 0.76 ± 0.05 (95% CI: 0.65, 0.86, p < 0.0001).
Conclusion: MRI-monitoring of disease activity would be helpful for assessment the risk of pospartum relapse in routine practice and can help to decide on the timing of the resumption of therapy. The presence of contrast enhancing lesions first months after birth increased the probability of relapse by 5.8 times (95% CI: 2,8; 9,9, p < 0.0001; sensitivity 63,4 %, specificity 88 %).
Disclosure: M Shumilina: has recieved and dedicated to research support fees for board membership, consultancy or speaking, or grants, in the last 3 years from Novartis, Biocad, Sanofi/Genzyme, Roche, Johnson & Johnson/ Janssen, R-Pharm and Generium.
E Evdoshenko: has recieved and dedicated to research support fees for board membership, consultancy or speaking, or grants, in the last 3 years from Biogen Idec, Sanofi, Genzyme and Generium.
E Kairbekova: nothing to disclose.
Abstract: EP1368
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - MS and gender
Introduction: It is known that exacerbations in the first year after childbirth are associated with the progression of the disease. However, data on the evaluation of various factors on the postpartum relapse's risk is not enough.
Objective: to evaluate MRI data before and after pregnancy.
Methods: A retrospective analysis from 2011 to 2017 of SPbMS Center registry was performed. For the analysis, the data were selected during observation for 1 year after delivery and without the use of 2-line drugs during pregnancy and the first months after childbirth. MRI data before pregnancy (n=92) and 1-3 mo after delivery (n=94) were assessed. Statistical analysis was performed with the program GraphPad Prism v7.0
Results: 127 women (133 births) were enrolled in the study. In the patient milestones there was a relapsing-remitting MS. AAR during pregnancy significantly decreased to 0.08 (p < 0.0001) and returned to the previous level 0.5 after delivery (p < 0.0001). When registering contrast lesions (Gd +) before pregnancy, the probability of exacerbations after childbirth is increased by 2.2 times (95% CI 1.08-4.9, p = 0.048). The existence of Gd+ immediately after delivery increased the probability of exacerbation by 5.8 times (95% CI: 2.83, 9.93, p < 0.0001). AUC was 0.76 ± 0.05 (95% CI: 0.65, 0.86, p < 0.0001).
Conclusion: MRI-monitoring of disease activity would be helpful for assessment the risk of pospartum relapse in routine practice and can help to decide on the timing of the resumption of therapy. The presence of contrast enhancing lesions first months after birth increased the probability of relapse by 5.8 times (95% CI: 2,8; 9,9, p < 0.0001; sensitivity 63,4 %, specificity 88 %).
Disclosure: M Shumilina: has recieved and dedicated to research support fees for board membership, consultancy or speaking, or grants, in the last 3 years from Novartis, Biocad, Sanofi/Genzyme, Roche, Johnson & Johnson/ Janssen, R-Pharm and Generium.
E Evdoshenko: has recieved and dedicated to research support fees for board membership, consultancy or speaking, or grants, in the last 3 years from Biogen Idec, Sanofi, Genzyme and Generium.
E Kairbekova: nothing to disclose.